According to two new studies, a pioneering scanning device can instantly reveal an individual’s risk of type 2 diabetes through a non-invasive fingernail reading.

A new clinical trial of a ground-breaking phage-based molecular diagnostic, has been agreed. The trial is aimed at evaluating the performance of the phage assay as a first-line blood-based diagnostic for active pulmonary Tuberculosis.

Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, has opened a new, state-of-the-art facility.

Sygnature Discovery has established an in vivo LPS model of inflammation which can help understand life-limiting neuroinflammatory conditions like Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, and traumatic brain injuries and identify new drug targets.

Owlstone Medical has announced new data on the development of novel tests for the detection of liver disease.

New website for diagnostic and laboratory solutions.

Yourgene Health presented data demonstrating that prolonged storage of blood in EDTA tubes is compatible with non-invasive prenatal testing (NIPT) when using size selection to enrich the fetal fraction.

Aptamer Group plc and Neuro-Bio announce success in the development of Optimer binders to enable a lateral flow test for the early diagnosis of Alzheimer’s disease.

Personalis, Inc. has announced it will present new clinical data as scientific posters at the American Society of Clinical Oncology Annual Meeting 2023, which convenes from June 2-6, 2023, in Chicago, Ill.

Thermo Fisher Scientific has announced it is making ImmunoCAP™ Specific IgE tests available to more patients across the U.S.